China Device Reforms Aplenty: Multiple Regulatory Changes Are Imminent
This article was originally published in The Gray Sheet
New rules relating to unannounced inspections, expanded good manufacturing practice requirements and revised product classification rules will each kick in the next four to five months, while new requirements pertaining to the submission of clinical trial records recently took effect.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.